Seeberger A, Ziegler K
Institut für Pharmakologie und Toxikologie, Justus-Liebig Universität Giessen, Federal Republic of Germany.
Biochem Pharmacol. 1993 Feb 24;45(4):917-25. doi: 10.1016/0006-2952(93)90177-x.
To define the endogenous transport system responsible for the hepatocellular uptake of hydrophilic linear peptides, interactions between the cationic renin-inhibitor, [5(4-amino-piperidyl-1-carbonyl-L-2,6[3H]phenyl-alanyl-beta-alanyl(4S- amino-3S-hydroxy-5-cyclo-hexyl)-pentan-carbonyl-L-isoleucyl-ami nom ethyl-4-amino-2-methyl-pyrimidine-citrat] (code number EMD 56133; EMD, E. Merck, Darmstadt) and substrates of endogenous transport systems of liver cells were studied in isolated rat hepatocytes. EMD 56133 competitively inhibited the uptake of ouabain (Ki = 75 microM) and vice versa (Ki = 200 microM). In contrast, the sodium-dependent as well as the sodium-independent uptake of cholate and the total uptake of taurocholate were non-competitively blocked, whereas EMD 56133 decreased the uptake of the cyclosomatostatin 008 in an uncompetitive manner. EMD 56133 did not interfere with transport systems for monovalent organic cations, amino acids and long chain fatty acids. The uptake of rifampicin, however, was increased in the presence of EMD 56133. The transport of EMD 56133 was non-competitively inhibited by cholate (Ki = 126 microM) and taurocholate (Ki = 44 microM), and uncompetitively inhibited by the linear peptide EMD 51921. In contrast, the uncharged compound ouabain (Ki = 200 microM) and the bivalent organic cation d-tubocurarine (Ki = 370 microM) competitively inhibited the uptake of the renin inhibitor. Several substrates of other endogenous transport systems (e.g. bilirubin, cyclopeptides, monovalent cations, dipeptides, amino acids, fatty acids, hexoses) did not interfere with the transport of EMD 56133. Our results suggest that transport systems for bivalent organic cations or uncharged compounds (ouabain) are able to eliminate the linear hydrophilic peptide tested.
为了确定负责肝细胞摄取亲水性线性肽的内源性转运系统,在分离的大鼠肝细胞中研究了阳离子肾素抑制剂[5(4-氨基-哌啶基-1-羰基-L-2,6[3H]苯丙氨酰-β-丙氨酰(4S-氨基-3S-羟基-5-环己基)-戊烷羰基-L-异亮氨酰-氨基甲基-4-氨基-2-甲基-嘧啶柠檬酸盐](编号EMD 56133;EMD,默克公司,达姆施塔特)与肝细胞内源性转运系统底物之间的相互作用。EMD 56133竞争性抑制哇巴因的摄取(Ki = 75 μM),反之亦然(Ki = 200 μM)。相比之下,胆酸盐的钠依赖性和非钠依赖性摄取以及牛磺胆酸盐的总摄取被非竞争性阻断,而EMD 56133以非竞争性方式降低环孢素008的摄取。EMD 56133不干扰单价有机阳离子、氨基酸和长链脂肪酸的转运系统。然而,在EMD 56133存在的情况下,利福平的摄取增加。EMD 56133的转运被胆酸盐(Ki = 126 μM)和牛磺胆酸盐(Ki = 44 μM)非竞争性抑制,并被线性肽EMD 51921非竞争性抑制。相比之下,不带电荷的化合物哇巴因(Ki = 200 μM)和二价有机阳离子筒箭毒碱(Ki = 370 μM)竞争性抑制肾素抑制剂的摄取。其他内源性转运系统的几种底物(如胆红素、环肽、单价阳离子、二肽、氨基酸、脂肪酸、己糖)不干扰EMD 56133的转运。我们的结果表明,二价有机阳离子或不带电荷的化合物(哇巴因)的转运系统能够消除所测试的线性亲水性肽。